Expansion extends potential use of Nu.Q® technology to Japan’s almost nine million cats Volition expects Nu.Q® Vet Feline Test to be the world’s first simple, affordable blood-based liquid biopsy test for feline cancer HENDERSON, Nev., Nov. 16, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces the expansion of … Continue reading "Volition Expands Contract with Fujifil…